{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:08:19Z","timestamp":1789013299316,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.yebeh.2026.111183","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T21:17:37Z","timestamp":1786223857000},"page":"111183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Exploring the caregiver journey through randomized controlled trials in dravet syndrome: insights from a cross-sectional survey"],"prefix":"10.1016","volume":"184","author":[{"given":"Caroline","family":"Delattre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"D\u2019Onofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Emmanuel","family":"Leiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5877-4074","authenticated-orcid":false,"given":"Rima","family":"Nabbout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.yebeh.2026.111183_b0005","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/1750-1172-8-176","article-title":"Encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsy","volume":"13","author":"Nabbout","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.yebeh.2026.111183_b0010","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/B978-0-444-52891-9.00065-8","article-title":"Dravet syndrome (severe myoclonic epilepsy in infancy)","volume":"111","author":"Dravet","year":"2013","journal-title":"Handb Clin Neurol"},{"issue":"6","key":"10.1016\/j.yebeh.2026.111183_b0015","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/epi.17239","article-title":"ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions","volume":"63","author":"Zuberi","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2026.111183_b0020","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.yebeh.2017.06.031","article-title":"Dravet syndrome: Characteristics, comorbidities, and caregiver concerns","volume":"74","author":"Villas","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2026.111183_b0025","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.yebeh.2017.08.029","article-title":"Development and content validation of a preliminary core set of patient- and caregiver-relevant outcomes for inclusion in a potential composite endpoint for Dravet Syndrome","volume":"78","author":"Nabbout","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2026.111183_b0030","doi-asserted-by":"crossref","unstructured":"Chemaly N, Kuchenbuch M, Teng T, Marie E, D'Onofrio G, Lo Barco T, et al. A European pilot study in Dravet Syndrome to delineate what really matters for the patients and families. Epilepsia Open. 2024 Feb;9(1):388-396. doi: 10.1002\/epi4.12557. Epub 2023 May 17. PMID: 34747137; PMCID: PMC10839355.","DOI":"10.1002\/epi4.12557"},{"issue":"9242","key":"10.1016\/j.yebeh.2026.111183_b0035","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","article-title":"Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial","volume":"356","author":"Chiron","year":"2000","journal-title":"STICLO study group Lancet"},{"key":"10.1016\/j.yebeh.2026.111183_b0040","doi-asserted-by":"crossref","unstructured":"Claes L, Del-Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe P. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet. 2001 Jun;68(6):1327-32. doi: 10.1086\/320609. Epub 2001 May 15. PMID: 11359211; PMCID: PMC1226119.","DOI":"10.1086\/320609"},{"issue":"21","key":"10.1016\/j.yebeh.2026.111183_b0045","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"issue":"10216","key":"10.1016\/j.yebeh.2026.111183_b0050","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/S0140-6736(19)32500-0","article-title":"Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial","volume":"394","author":"Lagae","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.yebeh.2026.111183_b0055","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/jamaneurol.2019.4113","article-title":"Fenfluramine for treatment-resistant seizures in patients with dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial","volume":"77","author":"Nabbout","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2026.111183_b0060","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04940624."},{"key":"10.1016\/j.yebeh.2026.111183_b0065","doi-asserted-by":"crossref","unstructured":"Wirrell EC, Hood V, Knupp KG, Meskis MA, Nabbout R, Scheffer IE, et al. International consensus on diagnosis and management of Dravet syndrome. Epilepsia. 2022 Jul;63(7):1761-1777. doi: 10.1111\/epi.17274. Epub 2022 May 12. PMID: 35490361; PMCID: PMC9543220.","DOI":"10.1111\/epi.17274"},{"issue":"1","key":"10.1016\/j.yebeh.2026.111183_b0070","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13023-022-02357-y","article-title":"Patient involvement in rare diseases research: a scoping review of the literature and mixed method evaluation of Norwegian researchers' experiences and perceptions","volume":"17","author":"Velvin","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.yebeh.2026.111183_b0075","doi-asserted-by":"crossref","unstructured":"Miller I, Scheffer IE, Gunning B, Sanchez-Carpintero R, Gil-Nagel A, Perry MS, et al. Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial. JAMA Neurol. 2020 May 1;77(5):613-621. doi: 10.1001\/jamaneurol.2020.0073. Erratum in: JAMA Neurol. 2020 May 1;77(5):655. doi: 10.1001\/jamaneurol.2020.0749. PMID: 32119035; PMCID: PMC7052786.","DOI":"10.1001\/jamaneurol.2020.0073"},{"key":"10.1016\/j.yebeh.2026.111183_b0080","unstructured":"Takeda AES 2024. Soticlestat as Adjunctive Therapy in Children and Young Adults with Dravet Syndrome: The Phase 3 SKYLINE Clinical Trial."},{"key":"10.1016\/j.yebeh.2026.111183_b0085","doi-asserted-by":"crossref","unstructured":"Kerr WT, Reddy AS, Seo SH, Kok N, Stacey WC, Stern JM, et al. Increasing challenges to trial recruitment and conduct over time. Epilepsia. 2023 Oct;64(10):2625-2634. doi: 10.1111\/epi.17716. Epub 2023 Jul 25. PMID: 37440282; PMCID: PMC10592378.","DOI":"10.1111\/epi.17716"},{"issue":"4","key":"10.1016\/j.yebeh.2026.111183_b0090","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/0197-2456(94)90044-2","article-title":"Patient perception of a long-term clinical trial: experience using a close-out questionnaire in the Studies of Left Ventricular Dysfunction (SOLVD) trial. SOLVD Close-out Working Group","volume":"15","author":"Henzlova","year":"1994","journal-title":"Control Clin Trials"},{"issue":"3","key":"10.1016\/j.yebeh.2026.111183_b0095","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-039471","article-title":"Experiences and perceptions of patients with psoriatic arthritis participating in a trial of faecal microbiota transplantation: a nested qualitative study","volume":"11","author":"Kragsnaes","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.yebeh.2026.111183_b0100","doi-asserted-by":"crossref","unstructured":"Maloney C, Lyons KD, Li Z, Hegel M, Ahles TA, Bakitas M. Patient perspectives on participation in the ENABLE II randomized controlled trial of a concurrent oncology palliative care intervention: benefits and burdens. Palliat Med. 2013 Apr;27(4):375-83. doi: 10.1177\/0269216312445188. Epub 2012 May 9. PMID: 22573470; PMCID: PMC3657725.","DOI":"10.1177\/0269216312445188"},{"issue":"6","key":"10.1016\/j.yebeh.2026.111183_b0105","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-040829","article-title":"Experiences and perceptions of trial participants and healthcare professionals in the UK Frozen Shoulder Trial (UK FROST): a nested qualitative study","volume":"11","author":"Srikesavan","year":"2021","journal-title":"BMJ Open"},{"issue":"7","key":"10.1016\/j.yebeh.2026.111183_b0110","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1745-6215-7-32","article-title":"Duty, desire or indifference? a qualitative study of patient decisions about recruitment to an epilepsy treatment trial","volume":"12","author":"Canvin","year":"2006","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.yebeh.2026.111183_b0115","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13063-023-07091-9","article-title":"The impact of parent treatment preference and other factors on recruitment: lessons learned from a paediatric epilepsy randomised controlled trial","volume":"24","author":"Carter","year":"2023","journal-title":"Trials"},{"key":"10.1016\/j.yebeh.2026.111183_b0120","doi-asserted-by":"crossref","unstructured":"Forsythe LP, Szydlowski V, Murad MH, Ip S, Wang Z, Elraiyah TA, et al. A systematic review of approaches for engaging patients for research on rare diseases. J Gen Intern Med. 2014 Aug;29 Suppl 3 (Suppl3):S788-800. doi: 10.1007\/s11606-014-2895-9. PMID: 25047393; PMCID: PMC4124116.","DOI":"10.1007\/s11606-014-2895-9"},{"issue":"1","key":"10.1016\/j.yebeh.2026.111183_b0125","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1186\/s13023-024-03482-6","article-title":"Multi-stakeholder sessions on major innovation topics in rare disease clinical trials","volume":"19","author":"Bodden","year":"2024","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.yebeh.2026.111183_b0130","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13023-023-02853-9","article-title":"Together4RD position statement on collaboration between European reference networks and industry","volume":"18","author":"Hedley","year":"2023","journal-title":"Orphanet J Rare Dis"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505026003045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505026003045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:34:24Z","timestamp":1789011264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505026003045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":26,"alternative-id":["S1525505026003045"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2026.111183","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the caregiver journey through randomized controlled trials in dravet syndrome: insights from a cross-sectional survey","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2026.111183","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111183"}}